Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAX9C3)

• Drug Name: AZD3463 Drug Info
• Synonyms: AZD-3463; CS-1382; HY-15609; KB-154896

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 56599293
  CAS Number: CAS 1356962-20-3
  TTD Drug ID: DMAX9C3

Molecule-Related Drug Atlas

Drug(s) Targeting ALK tyrosine kinase receptor (ALK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[6]
Brigatinib	DM7W94S	Anaplastic large cell lymphoma	2A90.A	Approved	[7]
Repotrectinib	DM9FB2T	Non-small-cell lung cancer	2C25	Approved	[8]
Ceritinib	DMB920Z	Non-small-cell lung cancer	2C25.Y	Approved	[9]
Alectinib	DMP1I6Y	Lung cancer	2C25.0	Approved	[10]
Ensartinib	DMIKDCQ	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PF-06463922	DMKM7EW	Non-small-cell lung cancer	2C25.Y	Phase 2	[11]
AP26113	DMYBQEF	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]

Drug(s) Targeting IGF1R messenger RNA (IGF1R mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATL-1101	DM4XZU2	Psoriatic disorder	EA90	Preclinical	[13]
GSK-1838705A	DM4HLK3	Discovery agent	N.A.	Investigative	[14]
AG 1024	DMF0SPB	Discovery agent	N.A.	Investigative	[15]
PQ401	DMVNHTE	Discovery agent	N.A.	Investigative	[16]
GSK1511931	DMZUTXW	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ALK tyrosine kinase receptor (ALK)	TTPMQSO	ALK_HUMAN	Inhibitor	[2]
IGF1R messenger RNA (IGF1R mRNA)	TTQFBMY	IGF1R_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7706).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1801).
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
• [10] CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
• [11] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] Clinical pipeline report, company report or official report of Antisense Therapeutics.
• [14] Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
• [15] Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology. 1997 Apr;138(4):1427-33.
• [16] Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006 Apr;5(4):1079-86.
• [17] Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett. 2009 Jan 15;19(2):373-7.